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The aim of this study was to determine the influence of ABCB1, CYP2B6, and CYP3A4 genetic polymorphisms on 
methadone metabolism in patients with hepatitis C virus (HCV) undergoing methadone maintenance treatment (MMT). 
The study included 35 participants undergoing MMT, who were divided in three groups: HCV-positive (N=12), HCV-
negative (N=16), and HCV clinical remission (CR) (N=7). The concentrations of methadone and its main metabolite 
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) were determined with gas chromatography-mass spectrometry. 
The patients were genotyped for ABCB1 rs1045642, CYP2B6 rs3745274, CYP3A4 rs2242480, and CYP3A4 rs2740574 
polymorphisms. Differences between single nucleotide polymorphism (SNP) genotypes and methadone-to-EDDP ratio 
were analysed with one-way ANOVA, which showed no significant difference between the genes (p=0.3772 for ABCB1 
rs1045642, p=0.6909 for CYP2B6 rs3745274, and p=0.6533 for CYP3A4 rs2242480). None of the four analysed SNP 
genotypes correlated with methadone-to-EDDP concentration ratio. A major influence on it in hepatitis C-positive patients 
turned out to be the stage of liver damage.
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Methadone is a synthetic opioid used for detoxification 
and maintenance treatment of patients who are dependent 
on opiates, mainly heroin. In the liver it is metabolised to 
2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) 
through N-demethylation mediated by several cytochrome 
P450 (CYP) enzymes, including CYP3A4 and CYP2B6 
(1). The CYP3A4 enzyme metabolises both (R)- and (S)- 
methadone enantiomers, but the (S)-enantiomer is mostly 
metabolised by CYP2B6 (2, 3).
Methadone kinetics is also slightly affected by ABCB1 
genetic polymorphisms (4). In a study of their effects on 
methadone maintenance treatment (MMT) in 60 opioid-
dependent patients, Coller et al. (5) reported that ABCB1 
genetic variability influenced daily methadone requirements.
In addition, CYP gene variants may contribute to the 
risk of fatal methadone toxicity posed by high concentrations 
of unmetabolised methadone in plasma (6). The risk may 
be even greater in patients with liver damage caused by 
hepatitis C virus (HCV) infection, which is common in 
opioid dependency. Our earlier studies (7, 8) have shown 
that chronic overdose and liver insufficiency (damage) 
increase the amount of unmetabolised methadone and its 
toxicity, but we did not consider the influence of the ABCB1, 
CYP2B6, and CYP3A4 genes on methadone metabolism as 
one of the numerous factors that influence inter-individual 
variability in that respect. The aim of this study was 
therefore to address this gap and see if the ABCB1, CYP2B6, 
and CYP3A4 genetic polymorphisms affect methadone 
metabolism in patients on MMT.
MATERIALS AND METHODS
The study was conducted in accordance with the 
Declaration of Helsinki and was approved by the Ethics 
Committee of the University Hospital Split, Croatia (No. 
530-01/12-01/164). All patients signed informed consent 
to participation in the study.
Participants
Our study participants were 35 adult men aged ≥21 
years, who were in the MMT programme conducted by the 
Institute for Public Health of the Split-Dalmatia County, 
Croatia. To arrive to this number we first assessed for 
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eligibility 74 adult male heroin addicts in the programme 
according to the following inclusion criteria: male, 
Caucasian, at least 9 months on MMT with regular 
attendance, no HIV or HBV co-infection or infection, 
negative urine tests for the presence of heroin or other 
pharmacological substances that could interfere with 
methadone metabolism, and no liver cirrhosis or history of 
significant alcohol abuse. HCV-positive patients were 
receiving interferon therapy that does not interfere with 
methadone metabolism (9). Thirty-nine candidates who did 
not meet these criteria were excluded.
The remaining 35 participants were divided in groups 
according to their HCV status: HCV-negative (HCV-) 
(N=12), HCV positive (HCV+) (N=16), and those in clinical 
remission (HCV CR) (N=7). Their liver damage was 
assessed according to the fibrosis-4 (FIB-4) index as 
described elsewhere (10). They were receiving different 
recommended doses of oral methadone based on their 
clinical presentation, and these doses were not modified for 
at least six months before the study (Table 1).
Methadone and EDDP determination
For this study, methadone and EDDP concentrations 
were tested only in urine during three regular check-ups 15 
days apart. We took two urine samples per check-up; one 
immediately before and the other 90 min after oral 
methadone administration, which totalled six samples per 
participant. The samples were stored at 4 °C and analysed 
within 1–4 days as described in detail in our previous reports 
(8, 11). Methadone and EDDP concentrations were used to 
calculate their ratio (Table 1).
DNA analysis
Blood samples for DNA analysis were collected at 
regular check-ups and stored in EDTA tubes. DNA was 
isolated with a commercial genomic DNA isolation kit 
(High Pure PCR Template Preparation Kit, Roche 
Diagnostics GmbH, Mannheim, Germany) according to the 
manufacturer’s instructions. Extracted DNA was quantified 
using a Qubit 4 fluorimeter (Thermo Fischer Scientific, 
Waltham, MA, USA).
SNP genotyping
Using the TaqMan® SNP genotyping assay (Thermo 
Fischer Scientific) and an Applied Biosystems 7500 real-
time polymerase chain reaction (RT-PCR) system (Applied 
Biosystems, Foster City, CA, USA) we genotyped for the 
following single-nucleotide polymorphisms (SNPs): 
ABCB1 rs1045642 (DME C_7586657_20), CYP2B6 SNP 
rs3745274 (DME C_7817765_60), CYP3A4 rs2242480 
(DME C_26201900_30), and CYP3A4 rs2740574 (DME 
C_1837671_50). RT-PCR and allelic discrimination 
analyses were performed according to the manufacturer’s 
instructions in a 25-mL reaction volume. The temperature 
program for RT-PCR was 60 °C for 1 min and 95 °C for 
10 min, followed by 50 cycles of 92 °C for 15 s and 60 °C 
for 90 s. SNP genotypes were determined using instrument 
software with the manual allele call option.
Statistical analysis
Statistics and differences between the samples and 
groups were tested by using GraphPad Prism version 8.0.0 
for Mac (GraphPad Software, San Diego, CA, USA). 
Hardy-Weinberg equilibrium, chi-square, and the p value 
were calculated with an on-line calculator (12).
RESULTS AND DISCUSSION
Methadone is converted to its inactive metabolites 
EDDP and EMDP by hepatic CYP450 enzymes. Its 
pharmacokinetics is individual, not only because of 
differences in sex, age, body weight, and use of other drugs, 
but also because of different allelic frequencies of genetic 
polymorphisms (2). Some earlier studies have already 
shown that allelic variations in the ABCB1 rs1045642, 
CYP2B6 rs3745274, and CYP3A4 rs2242480 and rs2740574 
SNPs may affect the distribution of methadone in patients 
undergoing MMT (6, 13, 14).
Table 2 shows the genotypes of the four investigated 
SNP loci in DNA obtained from blood samples. Genotype 
frequencies were consistent with the Hardy-Weinberg 
equilibrium and did not significantly differ for any of the 
studied SNPs (the p value ranged from 0.55 to 0.93). Minor 
allele frequencies (MAF) (Table 2) were consistent with 
those presented in a meta study by Dennis et al. (15), in 
which they ranged between 24.5 and 50 % for ABCB1 
rs1045642 and between 24 and 39 % for CYP2B6 
rs3745274.
In contrast to ABCB1 and CYP2B6 SNPs, no mutated 
alleles were found in either of the analysed CYP3A4 SNPs 
(Figure 1).
We observed a small difference in wild and mutant 
genotypes between the ABCB1 and CYP2B6 genes. Patients 
with the ABCB1 AA and CYP2B6 TT genotype had a slower 
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Table 1 Average FIB-4 index, methadone-to-EDDP urine concentration ratio, and methadone dose received by study groups (N=35)
Parameters HCV-negative (n=12) HCV-positive (n=16) HCV clinical remission (n=7)
FIB-4 index 0.81 2.61 2.08
Methadone-to-EDDP urine 
concentration ratio 0.87 2.04 0.79
Methadone dose (mg) 83.2 85.0 62.5
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Table 2 Genotype and allele frequencies (%) by loci for the ABCB1, CYP2B6 and CYP3A4 genes in all participants (N=35)
Gene SNP Genotype n (%) Minor allele MAF (%)
Hardy-Weinberg equilibrium

















C 1.4 0.99 0.007 0.93CT 1 (2.9)
CC 0 (0)
Figure 1 Methadone-to-EDDP ratio in all patients with different ABCB1, CYP2B6, CYP3A4 480 and CYP3A4_574 variants. 
H – heterozygotes; M – mutant; wt – wild type
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Figure 2 Methadone-to-EDDP ratio in patients with different ABCB1and CYP2B6 variants by HCV status. H – heterozygotes; HCV- 
– HCV-negative group; HCV+ – HCV-positive group; HCV CR – group in HCV clinical remission ; M – mutant; wt – wild type
Figure 3 FIB-4 index in all patients with different ABCB1 and CYP2B6 variants. H – heterozygotes; M – mutant; wt – wild type
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methadone metabolism than those with the GG genotype. 
In both SNPs of the CYP3A4 gene the wild genotype had 
a slower methadone metabolism than the heterozygous 
genotype.
Although several studies have suggested an association 
between genetic variability and methadone metabolism, our 
results showed no significant difference in methadone-to-
EDDP ratio between the SNP genotypes. For ABCB1 
rs1045642 it was p=0.3772 (ANOVA F=1.005), for CYP2B6 
rs3745274 p=0.6909 (F=0.374), and for CYP3A4 rs2242480 
p=0.6533 (F=0.4313).
Even within the groups divided by HCV status this 
difference was not significant (p>0.05) (Figure 2). In the 
HCV+ group, the methadone-to-EDDP ratio was similar 
for all three ABCB1 genotypes and slightly higher in patients 
with the mutated CYP2B6 genotype.
The liver is the primary target organ of HCV infection 
and is the main organ responsible for metabolism of drugs. 
Wu et al. (16) reported that HCV affected methadone 
metabolism in MMT patients. Our results seem to confirm 
this finding, as the severity of liver damage (median FIB-4 
index) was the highest in HCV patients, who also showed 
the slowest methadone metabolism (the highest methadone-
to-EDDP ratio; Table 1).
Figure 3 shows FIB-4 indices relative to the ABCB1 
and CYP2B6 gene polymorphisms for all 35 patients. The 
median FIB-4 index in both examined genes was higher in 
patients with the mutated genotype. However, we found no 
statistically significant difference in FIB-4 index between 
the SNP genotypes. For ABCB1 rs1045642 it was p=0.4465 
(ANOVA F=0.8269) and for CYP2B6 rs3745274 p=0.1551 
(F=1.977).
In conclusion, our study found no significant influence 
of the established genetic polymorphisms in our patients 
with methadone metabolism. Similar has been reported by 
Fonseca et. al. (17), who found negligible impact of the 
CYP3A5, CYP2B6, CYP2C9, CYP2C19, and ABCB1 
genetic polymorphisms on S-methadone metabolite plasma 
concentrations (16).
The only major influence on the methadone-to-EDDP 
ratio in HCV+ patients we found was the stage of liver 
damage. HCV- and HCV+ patients were taking similar 
methadone doses. The FIB-4 index and the methadone-to-
EDDP ratio in HCV- patients were lower, regardless of the 
genotype.
However, our conclusion should be taken with reserve, 
as this study had a small sample size. Future research should 
therefore involve more MMT patients.
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Polimorfizmi gena ABCB1, CYP2B6 i CYP3A4 ne utječu na metadonsku terapiju održavanja u bolesnika s HCV-om
Cilj ovoga istraživanja bio je utvrditi utjecaj polimorfizama gena ABCB1, CYP2B6 i CYP3A4 na metabolizam metadona 
u bolesnika/ovisnika s pozitivnim nalazom virusa hepatitisa C (HCV) na metadonskoj terapiji održavanja. Istraživanje 
je provedeno na uzorku od 35 sudionika na metadonskoj terapiji održavanja, podijeljenih u sljedeće skupine: HCV pozitivni 
(N=12), HCV negativni (N=16) i oni s kliničkom remisijom HCV-a (CR) (N=7). Koncentracije metadona i njegova 
glavnog metabolita 2-etiliden-1,5-dimetil-3,3-difenilpirolidina (EDDP) utvrđene su plinskom kromatografijom – masenom 
spektrometrijom. U sudionika su analizirani genski polimorfizmi ABCB1 rs1045642, CYP2B6 rs3745274, CYP3A4 
rs2242480 i CYP3A4 rs2740574. Jednosmjerna analiza varijance (engl. one-way ANOVA) nije pokazala statistički značajne 
razlike između genotipova jednonukleotidnih polimorfizama (engl. single-nucleotide polymorphism, krat. SNP) u omjeru 
koncentracije metadona i EDDP-a (p=0,3772 za ABCB1 rs1045642; p=0,6909 za CYP2B6 rs3745274 F=0,374 i p=0,6533 
za CYP3A4 rs2242480). Nijedan od četiriju analiziranih SNP genotipova nije korelirao s omjerom koncentracije metadona 
i EDDP-a. U bolesnika/ovisnika koji su bili pozitivni na HCV na taj je omjer ponajviše utjecao stupanj oštećenja jetre.
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